Keith Berman, MPH, MBA
Consultant, HEALTH RESEARCH ASSOCIATES
Member of the Healthcare Council
Council Member Biography
Keith Berman, MPH, MBA, founded Health Research Associates in 1996. HRA provides reimbursement consulting, business development and market research services to leading biopharmaceuticals, blood products and medical device manufacturers and suppliers. Previously, Mr. Berman worked for ten years in product development, reimbursement development, and market research roles at Baxter Healthcare, Siemens Medical, and MiniMed Technologies (now a Medtronic division). Since 1989, he has also served as editor of International Blood/Plasma News, an blood products industry newsletter. (This is me - Update Profile)
Employment History
- 1996 - present
- Consultant, HEALTH RESEARCH ASSOCIATES
GLG NewsSM Analyses by Keith Berman, MPH, MBA(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
Talecris Biotherapeutics Proposes IPO; Hits Favorable Timing Window
September 23, 2009
Keith Berman, MPH, MBA, Consultant, HEALTH RESEARCH ASSOCIATES
Talecris Joins Crowd of Stock Offerings | www.newsobserver.com
Talecris Biotherapeutics and its two private equity owners -- Cerberus Capital Management and Ampersand Ventures -- are counting on the third time being the charm with their new IPO slated to sell 44.7 million shares at a target price of $18 to $20 each. About $515 million of these funds are earmarked...
-
FDA Approves CSL's RiaSTAP Human Fibrinogen Product
January 22, 2009
Keith Berman, MPH, MBA, Consultant, HEALTH RESEARCH ASSOCIATES
CSL Behring Receives FDA Approval of RiaSTAP, First and Only Approved Treatmetn of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency | www.cslbehring.com
Rabies Surveillance in the United States during 2007CSL Behring's human fibrinogen concentrate, sold for years in Europe as Haemocomplettan P, will be welcomed as a treatment for bleeding problems in U.S. patients with a rare genetic absence or deficiency of this critical clotting protein. ...
-
CSL Gets FDA Approval for Its RiaSTAP Fibrinogen Product
January 20, 2009
Keith Berman, MPH, MBA, Consultant, HEALTH RESEARCH ASSOCIATES
CSL Behring Receives FDA Approval of RiaSTAP, First and Only Approved Treatmetn of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency | www.cslbehring.com
CSL Behring's human fibrinogen concentrate RiaSTAP, sold for years in Europe as Haemocomplettan P, will be welcomed for management of bleeding problems in U.S. patients with a rare genetic absence or deficiency of this critical clotting protein. RiaSTAP will eliminate the need for infusions of...
-
Highly Promising Phase III Trial of Baxter's IVIg for Alzheimer's Disease Begins
September 29, 2008
Keith Berman, MPH, MBA, Consultant, HEALTH RESEARCH ASSOCIATES
Baxter Initiates Phase III Trial for the Treatment of Alzheimer's Disease | www.baxter.com
Not surprisingly, everything tried thus far to slow the relentless progression of Alzheimer's disease has failed. But if strong efficacy signals from two pilot studies and a recently completed Phase II trial of human immunoglobulin (IVIg) are confirmed in a Phase III trial scheduled to startnext...
Leading institutions connect with Keith Berman, MPH, MBA through GLG
GLG Study Groups with Keith Berman, MPH, MBA(?)
| Study Group Name | No. Members |
|---|---|
| Economic Experts on Managed Care | 716 |
| Medicare Experts | 495 |
GLG Live Meetings with Keith Berman, MPH, MBA(?)
Keith Berman, MPH, MBA has not participated in any GLG Live Meetings.